In the FY2026 Q2 overview, revenue was revised upward for the full-year forecast. Core operating profit increased, driven by expanded contributions from key products such as Orgovix in the US market. The full-year forecast was partially revised and the year-end dividend is planned at 15 yen per share.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4506","jir_company_name":"Sumitomo Pharma Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-10-30","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/10\/4506-20261030-04.pdf","jir_short_summary":"In the FY2026 Q2 overview, revenue was revised upward for the full-year forecast. Core operating profit increased, driven by expanded contributions from key products such as Orgovix in the US market. The full-year forecast was partially revised and the year-end dividend is planned at 15 yen per share.","jir_summary":"### Earnings Overview\nFY2026 Q2 results were supported by strength in certain regions, including contributions from the US market, with revenue increasing to 266.5 billion yen year-over-year. Although gross profit expanded despite rising costs, increases in selling, general and administrative expenses and R&D expenses pressured profits. While core operating profit has room for improvement, the company raised its full-year outlook reflecting revisions made at the beginning of the fiscal year.\n\n### Outlook and Dividends\nThe full-year forecast was revised taking into account foreign exchange impact, and a year-end dividend of 15 yen per share is planned. Milestone achievements in the US market centered on Orgovix are expected to continue to support revenue uplift. R&D expenses are expected to increase mainly in oncology and neuropsychiatric areas, but overall the company expects to remain on a growth trajectory.","jir_financial_highlights":"Revenue: 2,665 (Year-over-Year +17.3%)\nCost of Sales: 1,235 (Year-over-Year +37.7%)\nGross Profit: 1,430 (Year-over-Year +4.0%)\nOperating Income: 962 (Year-over-Year -56.0%)\nNet Income Attributable to Owners of Parent: 382 (Year-over-Year -61.3%)\nFull-year Forecast (Exchange Rate): 1$ = 157.00 yen (Raised from previous forecast)","jir_category":"","jir_hashtags":"#SumitomoPharma, #Earnings, #EarningsGuidanceRevision, #ResearchAndDevelopment, #USMarket","jir_key_figures":"Revenue: 2,665 hundred million yen (Year-over-Year +17.3%)\nCost of Sales: 1,235 hundred million yen (Year-over-Year +37.7%)\nOperating Income: 962 hundred million yen (Year-over-Year -56.0%)","jir_meta_title":"Sumitomo Pharma Co., Ltd. FY2026 Q2 Earnings Overview & Growth Outlook\uff5c2026-10-30","jir_meta_description":"Summary of Sumitomo Pharma Co., Ltd.'s FY2026 Q2 earnings: revenue revised upward for the full-year forecast, expanded contributions from key products in the US market, and commentary on dividend outlook and R&D spending trends.","jir_og_title":"Sumitomo Pharma Co., Ltd.\uff5cFY2026 Q2 Earnings Overview and Revised Forecast","jir_og_description":"Key points from the FY2026 Q2 results: revenue growth, revisions to the full-year forecast, year-end dividend, and trends for major products.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 2Q\\\",\\\"2026 2Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[2265,2665]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 2Q\\\",\\\"2026 2Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[896,962]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Revenue Composition\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Japan\\\",\\\"US\\\",\\\"Other\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[885,2105,273]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Gross Margin Trend\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"2025 2Q\\\",\\\"2026 2Q\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Gross Margin\\\",\\\"data\\\":[54.5,58.0]}]},\\\"options\\\":{}}\"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Forecast vs Actual Comparison\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2026 Forecast\\\",\\\"FY2026 Revised Forecast\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[5400,5650]}]},\\\"options\\\":{}}\"}]","ir_related_company":7612,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-138891","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n